Nature reviews. Immunology, Journal Year: 2025, Volume and Issue: unknown
Published: April 11, 2025
Language: Английский
Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)
Published: Jan. 30, 2025
Abstract Background Colorectal cancer (CRC) has high incidence and mortality rates, with severe prognoses during invasion metastasis stages. Despite advancements in diagnostic therapeutic technologies, the impact of tumour microenvironment, particularly extracellular matrix (ECM) stiffness, on CRC progression is not fully understood. Methods This study included 107 patients. Tumour stiffness was assessed using magnetic resonance elastography (MRE), collagen ratio analysed Masson staining. cell lines were cultured matrices varying followed by transcriptome sequencing to identify stiffness-related genes. An HSF4 knockout model different ECM evaluate effects proliferation, migration, vitro vivo. Results significantly higher than normal tissue positively correlated content TNM staging. High-stiffness regulated functions signalling pathways. High (heat shock transcriptional factor 4) expression strongly associated poor prognosis. increased stages, its inhibited invasion, especially high-stiffness matrices. In vivo experiments confirmed that promoted growth metastasis, independent protein increase. Conclusions reveals promotes proliferation regulating EMT-related pathways through HSF4. could be valuable targets for prognostic assessment intervention CRC.
Language: Английский
Citations
4
Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)
Published: Jan. 11, 2025
Abstract Immune checkpoint therapies have spearheaded drug innovation over the last decade, propelling cancer treatments toward a new era of precision therapies. Nonetheless, challenges low response rates and prevalent resistance underscore imperative for deeper understanding tumor microenvironment (TME) pursuit novel targets. Recent findings revealed profound impacts biomechanical forces within on immune surveillance progression in both murine models clinical settings. Furthermore, pharmacological or genetic manipulation mechanical checkpoints, such as PIEZO1, DDR1, YAP/TAZ, TRPV4, has shown remarkable potential activation eradication tumors. In this review, we delved into underlying mechanisms resulting intricate biological meaning TME, focusing mainly extracellular matrix, stiffness cells, synapses. We also summarized methodologies employed research translation derived from current evidence. This comprehensive review biomechanics will enhance functional role provide basic knowledge discovery therapeutic
Language: Английский
Citations
1
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 906 - 906
Published: March 6, 2025
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy targeting the PD-1/PD-L1 axis has revolutionized treatment, providing durable responses in subset patients. However, with fewer than 50% patients achieving significant benefits, there is critical need to expand therapeutic strategies. This review explores emerging targets immune checkpoint inhibition beyond PD-1/PD-L1, including CTLA-4, TIGIT, LAG-3, TIM-3, NKG2A, and CD39/CD73. We highlight biological basis CD8 T cell exhaustion shaping antitumor response. Novel approaches additional inhibitory receptors (IR) are discussed, focus on their distinct mechanisms action combinatory potential existing therapies. Despite advancements, challenges remain overcoming resistance optimizing patient selection. underscores importance dual blockade innovative bispecific antibody engineering maximize outcomes for NSCLC
Language: Английский
Citations
1
Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 119636 - 119636
Published: March 1, 2025
Language: Английский
Citations
1
Cancer Cell, Journal Year: 2025, Volume and Issue: 43(4), P. 665 - 679
Published: April 1, 2025
Language: Английский
Citations
1
Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(10), P. 965 - 981
Published: July 15, 2024
Glioma, the most common primary malignant tumor in central nervous system (CNS), lacks effective treatments, and >60% of cases are glioblastoma (GBM), aggressive form. Despite advances immunotherapy, GBM remains highly resistant. Approaches that target antigens expedite development immunotherapies, including personalized tumor-specific vaccines, patient-specific selection, dendritic cell (DC) chimeric antigen receptor (CAR) T (TCR) cells. Recent studies show promising results treating lower-grade glioma (LGG), fostering hope for future immunotherapy. This review discusses vaccines against glioma, preclinical models immunological research, role CD4
Language: Английский
Citations
8
Cancer Letters, Journal Year: 2024, Volume and Issue: 611, P. 217385 - 217385
Published: Dec. 6, 2024
Language: Английский
Citations
7
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Aug. 16, 2024
Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efficacy in activating T cells oligodendrocyte-like against various cancers. Preclinical studies mouse models suggest that therapies CD276 may outperform PD1/PD-L1 blockade. However, data from indicate a significant non-responsive population to anti-CD276 treatment, with the mechanisms of resistance still unclear. In this study, we evaluate activity antibodies chemically-induced murine model head neck squamous cell carcinoma. Using induced orthotopic carcinogenesis, identify ITGB6 as key gene mediating differential responses treatment. Through single-cell RNA sequencing gene-knockout models, find regulates expression tumor-associated chemokine CX3CL1, which recruits activates PF4+ macrophages express high levels CX3CR1. Inhibition CX3CL1-CX3CR1 axis suppresses infiltration secretion CXCL16 by macrophages, thereby reinvigorating cytotoxic CXCR6+ CD8+ enhancing sensitivity Further investigations demonstrate inhibiting restores PD1 mice resistant anti-PD1 summary, our research reveals mechanism associated immune checkpoint inhibitor therapy identifies potential targets overcome cancer Response rate based immunotherapy remains suboptimal patients cancer. Here, carcinoma, authors show tumor promotes therapy, accumulation dysfunction.
Language: Английский
Citations
6
Translational Oncology, Journal Year: 2024, Volume and Issue: 49, P. 102113 - 102113
Published: Aug. 30, 2024
Gastric cancer (GC) remains a significant global health challenge with poor prognosis, partly due to its ability evade the immune system. The extracellular matrix (ECM), particularly collagen, plays crucial role in tumor evasion, but underlying mechanisms are not fully understood. This study investigates of collagen ECM promoting evasion gastric by activating IL4I1-AHR signaling pathway.
Language: Английский
Citations
5
Nature Biomedical Engineering, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 25, 2024
Language: Английский
Citations
4